Special Import - Mounjaro - Kwikpen 7.5 mg - 1pen/4doses

Special Import - Mounjaro - Kwikpen 7.5 mg - 1pen/4doses

Description:

Mounjaro kwikpen 7.5 mg is a prescription injectable medicine containing tirzepatide, used in adults with type 2 diabetes to improve blood sugar control and support medical weight management as part of a comprehensive plan including diet and exercise. It is supplied as a prefilled, multi‑dose pen (1 pen/4 doses) for once‑weekly subcutaneous injection. Tirzepatide is a dual glucose‑dependent insulinotropic polypeptide (GIP) and glucagon‑like peptide‑1 (GLP‑1) receptor agonist that helps regulate insulin secretion, reduce glucagon levels, slow gastric emptying, and decrease appetite, leading to better glycemic control and clinically significant weight reduction in many patients.

Indications:

• Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
• May be used as monotherapy when metformin is contraindicated or not tolerated, or in combination with other antihyperglycemic agents (such as metformin, SGLT2 inhibitors, or insulin) as directed by a healthcare professional.
• Helps reduce fasting and post‑prandial blood glucose levels.
• Supports medically supervised weight loss and reduction of obesity‑related risk factors in adults with type 2 diabetes.
• May help lower the risk of long‑term complications of poorly controlled type 2 diabetes when used as part of a comprehensive management plan.

Active Ingredients / Key Components:

• Tirzepatide – 7.5 mg per dose (active ingredient; dual GIP/GLP‑1 receptor agonist).
• Excipients – includes stabilizers, buffering agents, and tonicity adjusters commonly used in injectable solutions (exact excipient list and concentrations , please check the product leaflet or the manufacturer’s official website; refer to the official package leaflet for full composition).
• Each kwikpen delivers 4 subcutaneous doses of tirzepatide 7.5 mg (total of 30 mg tirzepatide per pen).

Dosage & Administration / How to Use:

• Use only as prescribed by your endocrinologist or healthcare provider. Do not change your dose without medical advice.
• Mounjaro is administered once weekly by subcutaneous injection in the abdomen, thigh, or upper arm. Rotate injection sites with each dose to reduce the risk of local reactions.
• The 7.5 mg strength is typically used after an initial titration period from lower doses (such as 2.5 mg and 5 mg) to improve tolerability; your doctor will determine your appropriate starting dose and titration schedule.
• The kwikpen is a prefilled, multi‑dose pen containing 4 doses; follow the step‑by‑step instructions in the patient leaflet for attaching a new needle, priming (if required), dialing the dose, injecting, and safely disposing of needles.
• Administer once weekly on the same day each week, at any time of day, with or without food. If necessary, you may change the day of weekly administration as long as the time between two doses is at least 3 days (72 hours).
• If you miss a dose and it is within 4 days (96 hours) of the scheduled time, inject the dose as soon as possible and then resume your regular weekly schedule. If more than 4 days have passed, skip the missed dose and take the next dose on the regularly scheduled day. Do not inject two doses within 3 days of each other.
• Do not share your kwikpen with anyone else, even if the needle is changed, to avoid cross‑infection and serious health risks.
• Patients using other glucose‑lowering medicines (especially insulin or sulfonylureas) may require dose adjustments to reduce the risk of hypoglycemia; this must be managed by a healthcare professional.

Clinical Benefits:

• Improves glycemic control in adults with type 2 diabetes by enhancing glucose‑dependent insulin secretion and reducing inappropriate glucagon release.
• Supports clinically meaningful weight loss by reducing appetite, increasing satiety, and slowing gastric emptying, which can help decrease caloric intake.
• Helps lower fasting plasma glucose and post‑meal blood sugar excursions, contributing to improved HbA1c levels over time.
• May reduce the need for higher doses of other antihyperglycemic medications and can support simplification of complex diabetes regimens under medical supervision.
• Once‑weekly dosing with a kwikpen device enhances convenience and may improve treatment adherence compared to daily injections.
• By improving blood sugar control and supporting weight reduction, it may help reduce the risk of diabetes‑related complications such as cardiovascular disease, kidney damage, and neuropathy when used as part of a comprehensive care plan.

Warnings & Contraindications:

• Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (mtc) or in patients with multiple endocrine neoplasia syndrome type 2 (men 2).
• Do not use if you have a known hypersensitivity to tirzepatide or any of the excipients in the formulation.
• Use with caution in patients with a history of pancreatitis; discontinue and seek urgent medical attention if you develop severe, persistent abdominal pain (with or without vomiting).
• May increase the risk of hypoglycemia when used in combination with insulin or insulin secretagogues (e.g., sulfonylureas); dose adjustments of concomitant medications may be required.
• Gastrointestinal adverse reactions (nausea, vomiting, diarrhea) may occur, especially during dose escalation; dehydration can result from severe vomiting or diarrhea, so maintain adequate fluid intake and contact your doctor if symptoms are intense or persistent.
• Not recommended for use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
• Limited data are available in patients with severe gastrointestinal disease, including severe gastroparesis; use with caution or avoid as advised by your physician.
• Consult your doctor before use if you are pregnant, planning pregnancy, or breastfeeding; tirzepatide is generally not recommended during pregnancy unless clearly needed, and an alternative therapy may be preferred.
• Inform your healthcare provider about all medicines you are taking, including oral diabetes medications, blood pressure medicines, lipid‑lowering drugs, and over‑the‑counter or herbal products, to assess potential interactions.
• Consult your doctor before use if you have kidney disease, liver disease, pancreatitis history, gallbladder disease, diabetic retinopathy, or cardiovascular disease.
• Not intended for use in children or adolescents unless specifically prescribed by a specialist.
• Consult your doctor before use if pregnant, nursing, taking medications, or have medical conditions such as liver disease, kidney disease, pancreatitis, gallbladder disease, or severe gastrointestinal disorders.
• Not intended to diagnose, treat, cure, or prevent any disease outside its approved medical indications.
• Keep out of reach of children.
• Use only under medical supervision and follow all instructions provided with the pen device to avoid dosing errors or injection‑site complications.

Side Effects:

• Common side effects: nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, indigestion, and injection‑site reactions (redness, itching, or mild swelling). These are often mild to moderate and may decrease over time as your body adjusts.
• Less common side effects: fatigue, dizziness, belching, gastroesophageal reflux, and mild increases in heart rate.
• Serious side effects (seek immediate medical attention): signs of pancreatitis (severe and persistent abdominal pain that may radiate to the back, with or without vomiting), signs of gallbladder disease (upper abdominal pain, fever, jaundice, clay‑colored stools), signs of allergic reaction (rash, itching, swelling of face or throat, severe dizziness, difficulty breathing), or severe dehydration due to persistent vomiting or diarrhea.
• Hypoglycemia: when used with insulin or sulfonylureas, symptoms may include sweating, tremor, palpitations, hunger, headache, confusion, or blurred vision. Check blood glucose regularly and contact your doctor if you experience recurrent low blood sugar.
• Any new, unusual, or worsening symptoms should be reported promptly to your healthcare provider.

Storage Instructions:

Store unopened pens in a refrigerator at 2–8°c. Do not freeze; discard the pen if it has been frozen. Protect from direct sunlight and excessive heat. After first use, follow the storage instructions in the package leaflet (some pens may be kept at room temperature for a limited time; exact duration is not specified in the provided information). Keep the pen cap on when not in use. Store in a cool, dry place away from direct sunlight and moisture. Keep container tightly closed and keep out of reach of children.

Specifications:

• Product type: prescription injectable medicine for type 2 diabetes management.
• Active ingredient: tirzepatide 7.5 mg per dose.
• Form: prefilled multi‑dose injection pen (kwikpen) for subcutaneous use.
• Pack size: 1 pen providing 4 doses (1pen/4doses).
• Intended users: adults with type 2 diabetes, under medical supervision.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.